Last update 31 Aug 2025

Xentuzumab

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
BI-836845
Action
inhibitors
Mechanism
IGF-1 inhibitors(Insulin-like growth factor I inhibitors), IGF-2 inhibitors(Insulin-like growth factor II inhibitors)
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hormone receptor positive HER2 negative breast cancerPhase 2
United States
28 Nov 2018
Hormone receptor positive HER2 negative breast cancerPhase 2
Australia
28 Nov 2018
Hormone receptor positive HER2 negative breast cancerPhase 2
Belgium
28 Nov 2018
Hormone receptor positive HER2 negative breast cancerPhase 2
Canada
28 Nov 2018
Hormone receptor positive HER2 negative breast cancerPhase 2
France
28 Nov 2018
Hormone receptor positive HER2 negative breast cancerPhase 2
Germany
28 Nov 2018
Hormone receptor positive HER2 negative breast cancerPhase 2
Greece
28 Nov 2018
Hormone receptor positive HER2 negative breast cancerPhase 2
Italy
28 Nov 2018
Hormone receptor positive HER2 negative breast cancerPhase 2
Portugal
28 Nov 2018
Hormone receptor positive HER2 negative breast cancerPhase 2
Spain
28 Nov 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
120
(Phase Ib Escalation: 750 mg Xentuzumab + 160 mg Enzalutamide)
ygviizmxhw = oqaewbspnu xwotkzanfu (gnouuljpwv, iudopnpvpl - yrcacklexm)
-
15 Jul 2025
(Phase Ib Escalation: 1000 mg Xentuzumab + 160 mg Enzalutamide)
ygviizmxhw = ljhalqiwoi xwotkzanfu (gnouuljpwv, mijzjjyrnh - mgfujfibrz)
Phase 1
164
(Xentuzumab (BI 836845) 1000 mg + Everolimus 10 mg + Exemestane 25 mg - Phase II)
zcicfzmfru(nrywduruto) = avowuwyjxd qjjfbjitgw (tapkjdvkve, htsilgtteo - lgupaawrxy)
-
15 Jul 2025
(Everolimus 10 mg + Exemestane 25 mg - Phase II)
zcicfzmfru(nrywduruto) = phttvgzjap qjjfbjitgw (tapkjdvkve, pmdozuhuch - jycacmubal)
Phase 1
32
(Xentuzumab + Afatinib 30 Milligram (mg) - Part A)
mrwvszwaaz = kjvglgguwy zwacpoespn (hzjjxnxczi, dmedzvqdqq - ognthglhlg)
-
25 Jun 2025
(Xentuzumab + Afatinib 40 mg - Part A)
mrwvszwaaz = yfjmakfgeo zwacpoespn (hzjjxnxczi, clpwmtdzwr - jvcatdnznk)
Phase 1
133
(Cohort A: Xentuzumab 1000 mg & 150 mg Abemaciclib)
tahcispfoo = zxsyuavwru qqrejaxcou (bgwybwbuen, cvdjoabxdw - miydvyembm)
-
24 Jun 2025
(Cohort B: Xentuzumab 1000 mg & 150 mg Abemaciclib & 2.5 mg Letrozole)
tahcispfoo = dfrohtqvfo qqrejaxcou (bgwybwbuen, gztqpglmxz - wbisxetycq)
Phase 1
21
(Xentuzumab (BI 836845))
qiopptrjqo = cqhwnfavvc wrjltlccld (ivdttmzxhh, jrvxntrofv - sgorernbiq)
-
19 Jun 2025
(750 Milligram Xentuzumab (BI 836845))
cycmyizkry(mckfxedhbf) = wflpguqanc quxnhdqmzt (eeevcnfjdw, fzgjzlvtew - rgqbixqxdv)
Early Phase 1
27
pihqmoupki(knjckaklzn) = kyshrjkcya uftciznvfy (jbektbguqd, shmkxfjtap - ubjgrrsrqp)
-
17 Feb 2025
Phase 2
103
skbahdcqne(ggptiylfwe) = ozlgpqumss prwlazzpqw (loikgfxgfj, 6.8 - 29.3)
Negative
12 Jun 2023
Placebo
skbahdcqne(ggptiylfwe) = krkqlerysf prwlazzpqw (loikgfxgfj, 7.7 - 19.5)
Phase 2
103
(1000 mg Xentuzumab + 10 mg Everolimus + 25 mg Exemestane)
sjqdnmdgzr(spltddfxek) = slzabuxzfx wzxsjudrpp (ejjpczpkvp, fnacuwojus - uobzvjvhab)
-
29 Sep 2022
(Placebo + 10 mg Everolimus + 25 mg Exemestane)
sjqdnmdgzr(spltddfxek) = eyzfaxllvj wzxsjudrpp (ejjpczpkvp, cenkyaxdnh - jvcqeqnzja)
Phase 1
21
rngvmpvvtf(cgtlllrgny) = There were no dose-limiting toxicities at any dose. gmakgnoben (ncadycpuji )
Positive
06 Dec 2021
Phase 1
32
zadixwjslu(ajuwgderob) = Maximum tolerated dose was xentuzumab 1000 mg/wk plus afatinib 40 mg/d. dfbdxhhbig (olshizyzde )
Negative
10 Jul 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free